EASL Recommendations on Treatment of Hepatitis C 2018
EASL Recommendations on Treatment of Hepatitis C 2018
复制标题
DOI：
10.1016/j.jhep.2018.03.026
复制
发表时间：
2018-08-01
影响因子：
25.7
通讯作者：
中科院分区：
文献类型：
--
作者：
丙型肝炎病毒（HCV）感染是慢性肝病的主要原因，全世界约有7100万慢性感染者。由于对丙型肝炎相关肝病的病理生理学理解的增强，以及诊断程序的发展和治疗和预防的改进，丙型肝炎相关肝病患者的临床护理已经取得了相当大的进展。这些欧洲肝脏研究协会关于丙型肝炎治疗的建议描述了2018年及以后急性和慢性丙型肝炎感染患者的最佳管理。(C) 2018年欧洲肝脏研究协会。Elsevier B.V.版权所有。
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.